Amid rumors of a potential sale by Teva of its Teva Active Pharmaceutical Ingredients unit, the generics giant has underlined the strength of the TAPI business and its increasingly standalone nature while acknowledging that it continuously reviews business opportunities.
A recent report in Bloomberg claimed that the generics giant was “weighing options for its active ingredients business, including a possible sale,” citing “people with knowledge of the matter.”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?